Technical Analysis for PPBT - Purple Biotech Ltd.

Grade Last Price % Change Price Change
F 4.43 -4.94% -0.23
PPBT closed down 4.94 percent on Thursday, April 22, 2021, on 73 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Up
Historical PPBT trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Stochastic Reached Overbought Strength 0.00%
Weak + Overbought Other 0.00%
Inside Day Range Contraction 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
50 DMA Resistance Bearish -4.94%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -4.94%
Pocket Pivot Bullish Swing Setup -4.94%
Above Upper BB Strength -4.94%
Older End-of-Day Signals for PPBT ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakdown about 6 hours ago
Down 5% about 6 hours ago
Possible Inside Day about 6 hours ago
Down 3% about 10 hours ago
Down 2 % about 10 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Purple Biotech Ltd. Description

Purple Biotech Ltd. (f/k/a Kitov Pharma Ltd.) (the “Company”; NASDAQ/TASE: KTOV) is a clinical-stage company focusing on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, to create successful long-lasting treatments for people with cancer. The Company’s oncology pipeline includes NT219 and CM24. NT219 is a small molecule targeting the novel cancer drug resistance pathways IRS1/2 and STAT3. The Company is currently advancing NT219 as a monotherapy treatment of advanced solid tumors and in combination with cetuximab for the treatment of recurrent or metastatic squamous cell carcinoma of head and neck cancer (SCCHN) in a phase 1/2 study. CM24 is a monoclonal antibody blocking CEACAM1, a novel immune checkpoint that supports tumor immune evasion and survival through multiple pathways. The Company plans to advance CM24 as a combination therapy with anti-PD-1 checkpoint inhibitors in selected cancer indications in a phase 1 study followed by a phase 2 for the treatment of non-small cell lung cancer and pancreatic cancer. The Company has entered into a clinical collaboration agreement, as amended, with Bristol Myers Squibb for the planned phase 1/2 clinical trials to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab (Opdivo®) in patients with non-small cell lung cancer and in combination with nivolumab in addition to nab-paclitaxel (ABRAXANE®) in patients with pancreatic cancer. The Company is also the owner of Consensi®, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension that was approved by the FDA for marketing in the U.S. Consensi® is being sold in the U.S. by Burke Therapeutics, the marketing partner of the Company’s U.S. distributor, Coeptis Pharmaceuticals. The Company has also partnered to commercialize Consensi in China and South Korea. The Company is relocating its corporate headquarters imminently to Rehovot, Israel.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Immune System Cancer Treatments Hypertension Non Small Cell Lung Cancer Tumor FDA Antineoplastic Drugs Osteoarthritis Pancreatic Cancer Advanced Solid Tumors Lung Cancer Breakthrough Therapy Checkpoint Inhibitor Novel Cancer Treatment Of Non Small Cell Lung Cancer Treatment Of Osteoarthritis Health Effects Of Tobacco Non Small Cell Lung Carcinoma Pd 1

Is PPBT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 14.4
52 Week Low 3.06
Average Volume 537,828
200-Day Moving Average 4.91
50-Day Moving Average 4.64
20-Day Moving Average 4.19
10-Day Moving Average 4.16
Average True Range 0.30
ADX 17.08
+DI 27.31
-DI 20.11
Chandelier Exit (Long, 3 ATRs ) 3.84
Chandelier Exit (Short, 3 ATRs ) 4.52
Upper Bollinger Band 4.58
Lower Bollinger Band 3.79
Percent B (%b) 0.81
BandWidth 19.02
MACD Line -0.06
MACD Signal Line -0.12
MACD Histogram 0.0608
Fundamentals Value
Market Cap 76.24 Million
Num Shares 17.2 Million
EPS -0.17
Price-to-Earnings (P/E) Ratio -26.69
Price-to-Sales 16.17
Price-to-Book 1.25
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.81
Resistance 3 (R3) 4.82 4.72 4.74
Resistance 2 (R2) 4.72 4.62 4.71 4.72
Resistance 1 (R1) 4.57 4.56 4.52 4.56 4.70
Pivot Point 4.47 4.47 4.44 4.46 4.47
Support 1 (S1) 4.32 4.37 4.27 4.31 4.16
Support 2 (S2) 4.22 4.31 4.21 4.14
Support 3 (S3) 4.07 4.22 4.12
Support 4 (S4) 4.06